| Literature DB >> 31062294 |
Stephen Wong1, Ram Mani2, Shabbar Danish3.
Abstract
Implantable neural stimulators represent an advanced treatment adjunct to medication for pharmacoresistant epilepsy and alternative for patients that are not good candidates for resective surgery. Three treatment modalities are currently FDA-approved: vagus nerve stimulation, responsive neurostimulation, and deep brain stimulation. These devices were originally trialed in very similar patient populations with focal epilepsy, but head-to-head comparison trials have not been performed. As such, device selection may be challenging due to large overlaps in clinical indications and efficacy. Here we will review the data reported in the original pivotal clinical trials as well as long-term experience with these technologies. We will highlight differences in their features and mechanisms of action which may help optimize device selection on a case-by-case basis.Entities:
Keywords: DBS; Neurostimulation; RNS; VNS; deep brain stimulation; epilepsy; responsive neurostimulation; seizures; vagus nerve stimulation
Mesh:
Year: 2019 PMID: 31062294 PMCID: PMC6554379 DOI: 10.1007/s13311-019-00727-2
Source DB: PubMed Journal: Neurotherapeutics ISSN: 1878-7479 Impact factor: 7.620